Bayer to urge approval of its Roundup settlement package
Bayer is seeking preliminary approval today from a federal judge on its proposed settlement on Roundup lawsuits that allege the product causes non-Hodgkins lymphoma cancer. The company has committed more than 9-and-a-half Billion dollars to resolve existing claims and for people who become ill in the future, standing by studies that have shown Roundup and glyphosate are safe for human use.
Users of Roundup would be able to opt out of the class-action settlement and retain their full legal rights. All litigation would be paused for four years, however. A scientific panel would be set up to assess in that time the link between Roundup and cancer.
Bayer says the cases that HAVE gone to trial have not correctly applied the law in which tens of millions of dollars have been awarded to plaintiffs.
On Friday, a federal appeals court upheld a $25 Million dollar jury verdict. Bayer says it will ask for a U.S. Supreme Court review.